Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | QDPR | P09417 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16553643 | 0.77 | PDK4 (0.54) | JAK2JAK1 | |
| SCHEMBL12079212 | 0.77 | JAK2 (0.52) | JAK2NUDT1JAK1JAK3 | |
| SCHEMBL16554303 | 0.75 | JAK2 (0.50) | JAK2NUDT1JAK1JAK3DRD2 | |
| Hydrochloric Acid SCHEMBL16553729 | 0.75 | JAK2 (0.50) | JAK2NUDT1JAK1JAK3DRD2 | |
| SCHEMBL2252811 | 0.75 | JAK2 (0.50) | JAK2NUDT1JAK1JAK3 | |
| SCHEMBL16553842 | 0.73 | JAK1 (0.70) | JAK2JAK1 | |
| SCHEMBL4159466 | 0.71 | KDM4E (0.54) | DRD2DRD4QDPR | |
| SCHEMBL2270706 | 0.71 | JAK2 (0.50) | JAK2NUDT1JAK1JAK3 | |
| SCHEMBL24090152 | 0.69 | NUDT1 (0.60) | JAK2NUDT1JAK1JAK3 | |
| SCHEMBL18367046 | 0.68 | JAK2 (0.77) | JAK2NUDT1JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | JAK2 2/4885NUDT1 1067/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.